PDE4-IN-9 is a potent PDE4 inhibitor with in vitro IC50 value of 1.4 μM against PDE4, demonstrating superior activity compared to rolipram (IC50 = 2.0 μM); it exhibits favorable in vivo efficacy in LPS-induced animal models of asthma/COPD and sepsis.